However, Paul Hudson, CEO of Sanofi, one of the world's leading biopharmaceutical companies, says executives may need to rein ...

Vera Therapeutics appointed Amgen and Seagen alum Matt Skelton as EVP of commercial. Frank Lane was appointed SVP and head of ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, drug pipeline outlook, the ...

Sanofi, Formation Bio and OpenAI have joined forces to build ... accelerate the delivery of new medicines and reshape ...

Robert is currently chief digital officer at the cruise line firm Viking Cruises and will join Sanofi on 15th June. His brief is to drive Sanofi’s digital, data and technology strategy ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

Along with Le Fur – who was CEO at Sanofi predecessor Sanofi-Aventis in 2007 and 2008 – eureKING's backers include Michael Kloss, former head of Panasonic Healthcare, who will serve as CEO of ...

"We were hopeful to get a larger market share this year," Novavax CEO John Jacobs said in an interview ... Novavax does not ...

“We reached almost 16% sales growth in the third quarter, illustrating the underlying strength of our portfolio,” said Sanofi CEO Paul Hudson, in a statement. “Our performance was boosted by ...

Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare disease targets.

Today, Formation Bio, together with OpenAI and Sanofi, introduced Muse, an advanced AI-powered tool developed to accelerate and improve drug development by optimizing patient recruitment for clinical ...